Update on Clinical Trials for Malignant Melanoma
作者： Paul Lorigan , Raffaele Califano , Ruth Board , Aidalena Abidin , Louise Carter
DOI: 10.5772/19168
关键词: Clinical research 、 Intensive care medicine 、 Medicine 、 Clinical trial 、 Vemurafenib 、 Treatment options 、 Melanoma 、 Ipilimumab
摘要: After more than 20 years of little improvement in the outcome for patients with malignant melanoma despite a huge international effort spanning basic and clinical research, last 2 have shown significant steps forward treatment options. This year has seen one new drug (Ipilimumab) being licensed second (vemurafenib) submitted approval. chapter focuses on key trials 5 years, gives an indication challenges ahead to ensure optimal use these effective therapies.
intechopen.com
manchester.ac.uk参考文章(57)
R. Kefford, H. Arkenau, M. P. Brown, M. Millward, J. R. Infante, G. V. Long, D. Ouellet, M. Curtis, P. F. Lebowitz, G. S. Falchook, Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. Journal of Clinical Oncology. ,vol. 28, pp. 8503- 8503 ,(2010) , 10.1200/JCO.2010.28.15_SUPPL.8503
J M Kirkwood, M H Strawderman, M S Ernstoff, T J Smith, E C Borden, R H Blum, Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. Journal of Clinical Oncology. ,vol. 14, pp. 7- 17 ,(1996) , 10.1200/JCO.1996.14.1.7
W. H. Kruit, S. Suciu, B. Dreno, V. Chiarion-Sileni, L. Mortier, C. Robert, M. Maio, V. G. Brichard, F. Lehmann, U. Keilholz, Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: A randomized open-label phase II study of the EORTC Melanoma Group (16032- 18031) Journal of Clinical Oncology. ,vol. 26, pp. 9065- 9065 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.9065
Paul B. Chapman, Lawrence H. Einhorn, Michael L. Meyers, Scott Saxman, Alicia N. Destro, Katherine S. Panageas, Colin B. Begg, Sanjiv S. Agarwala, Lynn M. Schuchter, Marc S. Ernstoff, Alan N. Houghton, John M. Kirkwood, Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma Journal of Clinical Oncology. ,vol. 17, pp. 2745- 2751 ,(1999) , 10.1200/JCO.1999.17.9.2745
Selma Ugurel, Gunter Rappl, Wolfgang Tilgen, Uwe Reinhold, Increased Serum Concentration of Angiogenic Factors in Malignant Melanoma Patients Correlates With Tumor Progression and Survival Journal of Clinical Oncology. ,vol. 19, pp. 577- 583 ,(2001) , 10.1200/JCO.2001.19.2.577
M.R. Middleton, J.J. Grob, N. Aaronson, G. Fierlbeck, W. Tilgen, S. Seiter, M. Gore, S. Aamdal, J. Cebon, A. Coates, B. Dreno, M. Henz, D. Schadendorf, A. Kapp, J. Weiss, U. Fraass, P. Statkevich, M. Muller, N. Thatcher, Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma Journal of Clinical Oncology. ,vol. 18, pp. 158- 166 ,(2000) , 10.1200/JCO.2000.18.1.158
J. M. Kirkwood, P. Lorigan, P. Hersey, A. Hauschild, C. Robert, D. McDermott, M. A. Marshall, J. Gomez-Navarro, J. Q. Liang, C. A. Bulanhagui, Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma Clinical Cancer Research. ,vol. 16, pp. 1042- 1048 ,(2010) , 10.1158/1078-0432.CCR-09-2033
Richard J. Klasa, Amanda M. Gillum, Robert E. Klem, Stanley R. Frankel, Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense & Nucleic Acid Drug Development. ,vol. 12, pp. 193- 213 ,(2002) , 10.1089/108729002760220798
Laura B Rosen, David D Ginty, Michael J Weber, Michael E Greenberg, Membrane depolarization and calcium influx stimulate MEK and MAP kinase via activation of Ras Neuron. ,vol. 12, pp. 1207- 1221 ,(1994) , 10.1016/0896-6273(94)90438-3
John A. Curtin, Jane Fridlyand, Toshiro Kageshita, Hetal N. Patel, Klaus J. Busam, Heinz Kutzner, Kwang-Hyun Cho, Setsuya Aiba, Eva-Bettina Bröcker, Philip E. LeBoit, Dan Pinkel, Boris C. Bastian, Distinct Sets of Genetic Alterations in Melanoma The New England Journal of Medicine. ,vol. 353, pp. 2135- 2147 ,(2005) , 10.1056/NEJMOA050092